Riskpilot← Back to searchSign inGet full accessVIGRESTADS APOTEK AS
ASActiveOrg 916939469Retail sale of pharmaceutical products · NACE 4773Est. 20166 employees
Revenue 2022
NOK 29,4M
-21% vs 2021
EBITDA margin
3.9%
-55% vs 2021
Equity ratio
49.4%
Financial strength
Net profit 2022
NOK 945K
-50% vs 2021
| Revenue | NOK 29,4M | -21% |
| EBITDA | NOK 1,1M | -55% |
| Net profit | NOK 945K | -50% |
| Total assets | NOK 7,8M | -7% |
| Equity | NOK 3,9M | +32% |
| Employees | 6 | — |
Legal name
VIGRESTADS APOTEK AS
Org number
916939469
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
30. mars 2016
Share capital
NOK 12 000 000
Employees
6 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Company purpose
Drive apotek, samt hva som naturlig kommer under dette, herunder å eie aksjer i andre virksomheter.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 26 295 | 32 914 | 33 546 | 37 290 | 29 393 |
| Staff expenses | −2 686 | −2 780 | −3 025 | −3 296 | −3 612 |
| EBITDA | 1 815 | 2 284 | 2 236 | 2 552 | 1 150 |
| Depreciation & amort. | −169 | −182 | −197 | −179 | −154 |
| EBIT | 1 647 | 2 102 | 2 038 | 2 374 | 995 |
| Net financials | −12 | −63 | −88 | 20 | 177 |
| Profit before tax | 1 635 | 2 039 | 1 950 | 2 393 | 1 173 |
| Tax | 373 | 449 | 433 | 519 | 228 |
| Net profit | 1 261 | 1 590 | 1 517 | 1 874 | 945 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 6 107 | 9 396 | 8 666 | 8 385 | 7 807 |
| Equity | 1 462 | 2 807 | 2 912 | 2 913 | 3 858 |
| Long-term debt | 605 | 412 | 1 087 | 705 | 37 |
| Short-term debt | 4 040 | 6 178 | 4 667 | 4 766 | 3 912 |
| Total debt | 4 645 | 6 590 | 5 753 | 5 471 | 3 949 |
EBITDA margin
3.9%
This company
15.8%
Market median
-75% vs market
20182022
Equity ratio
49.4%
This company
38.2%
Market median
+29% vs market
20182022
Return on equity
24.5%
This company
18.4%
Market median
+33% vs market
20182022
Net profit margin
3.2%
This company
8.1%
Market median
-60% vs market
20182022
Asset turnover
3.76×
This company
1.12×
Market median
+236% vs market
20182022
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20182022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AA Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2016 | |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of VIGRESTADS APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andreas Aleksander Christensen | Chief Executive Officer | 0 companies |
| Erik Franciscus Godefridus De Beer | Chairman | 0 companies |